Galanin/GalR1-3 system: A promising therapeutic target for myocardial ischemia/reperfusion injury.
Animals
Cardiotonic Agents
/ pharmacology
Creatine Kinase, MB Form
/ metabolism
Disease Models, Animal
Galanin
/ metabolism
Heart
/ drug effects
L-Lactate Dehydrogenase
/ metabolism
Ligands
Male
Myocardial Infarction
/ drug therapy
Myocardial Reperfusion Injury
/ drug therapy
Myocardium
/ metabolism
Rats
Rats, Wistar
Receptors, Galanin
/ metabolism
Modified galanin fragments
Myocardial ischemia/reperfusion injury
Myocardial protection
Rat
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
18
05
2018
revised:
11
09
2018
accepted:
28
09
2018
entrez:
16
12
2018
pubmed:
16
12
2018
medline:
27
3
2019
Statut:
ppublish
Résumé
N-terminal fragments of galanin (2-11) and (2-15) are critical for binding to GalR1-3 receptors, members of the G-protein-coupled receptor superfamily, and are involved in myocardial protection against ischemia/reperfusion (I/R) injury. This study was designed to synthesize novel GalR1-3 agonists with improved properties and evaluate their efficiency as cardioprotective agents. Peptide agonists were synthesized by the automatic solid phase method using Fmoc technology and purified by preparative HPLC. Their chemical structure was identified by
Identifiants
pubmed: 30551408
pii: S0753-3322(18)33563-7
doi: 10.1016/j.biopha.2018.09.182
pii:
doi:
Substances chimiques
Cardiotonic Agents
0
Ligands
0
Receptors, Galanin
0
Galanin
88813-36-9
L-Lactate Dehydrogenase
EC 1.1.1.27
Creatine Kinase, MB Form
EC 2.7.3.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1556-1562Informations de copyright
Copyright © 2018 Elsevier Masson SAS. All rights reserved.